

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 89101237.9

(51) Int. Cl. 4: A61K 47/00 , A61K 31/195

(22) Date of filing: 25.01.89

(30) Priority: 27.01.88 JP 16683/88

(43) Date of publication of application:
09.08.89 Bulletin 89/32

(54) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: Senju Pharmaceutical Co., Ltd.
6-1, Hiranomachi 3-chome Higashi-ku
Osaka(JP)

Applicant: A.H. ROBINS COMPANY,
INCORPORATED
1407 Cummings Drive
Richmond Virginia 23220(US)


(72) Inventor: Ogawa, Takahiro

8-23, Atagoyama
Nishinomiya-shi Hyogo(JP)
Inventor: Kuribayashi, Yoshikazu
2-10, Nakagocho 1-chome Nadaku
Kobe-shi Hyogo(JP)
Inventor: Ushio, Kazumichi
6-13, Kamiohichi 1-chome
Nishinomiya-shi Hyogo(JP)
Inventor: Ohtori, Akira
3454-11, Gakuen-midorigaoka 2-chome
Nara-shi Nara(JP)

(74) Representative: von Kreisler, Alek,
Dipl.-Chem. et al
Patentanwälte Von Kreisler-Selting-Werner
Deichmannhaus am Hauptbahnhof
D-5000 Köln 1(DE)

(54) A locally administrable therapeutic composition for inflammatory disease.

(57) This invention relates to a locally administrable therapeutic composition for inflammatory disease which is characterized by comprising benzoylphenetylacetic acid of the formula



(wherein R is a hydrogen or halogen atom), or a salt thereof, or the hydrate of said acid or salt, as active ingredient.

The ophthalmic composition according to the invention can treat effectively inflammatory eye disease by topical application, is not irritant to the eye, and has a superior effect to conventional drugs of the same or similar type.

The aqueous composition prepared in accordance with this invention has an excellent stability and can be used advantageously as a nasal or otic composition as well as ophthalmic one in the treatment of inflammatory otic or nasal disease.

EP 0 326 915 A1

A locally administrable therapeutic composition for inflammatory disease

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a locally administrable therapeutic composition for inflammatory eye disease as well as nasal or otic inflammatory disease.

More particularly, it relates to a locally administrable therapeutic composition for inflammatory eye as well as for nasal or otic inflammatory disease, which contains as active ingredient a benzoylphenylacetic acid derivative, a salt thereof or the hydrate of said acid or salt.

The other object of the present invention is to provide a stable locally administrable aqueous composition such as eye drop, otic composition and nasal composition containing the above compounds.

15

2. Description of the Prior Art

That certain benzoylphenylacetic acid derivatives, when orally administered, exhibit antiinflammatory activity has been reported in detail in Journal of Medicinal Chemistry, Volume 27, pages 1370-1388 (1984), among others. Furthermore, Japanese Laid Open Patent Publication No. 126124/1987 describes pharmaceutical compositions for percutaneous administration which contain these compounds. However, none of the published literature inclusive of the above-mentioned patent specification contains any description indicating or suggesting that these medicinal substances are effective against inflammatory disease of the eye, nose or ear when they are administered topically.

For the treatment, with topical application of drugs, of inflammatory ophthalmopathy such as uveitis and conjunctivitis which are most frequently observed in ophthalmological field, steroid drugs such as dexamethazone have so far been employed. Topical application of steroid drugs to eye has some apprehension of increasing intraocular pressure to cause glaucoma. And, there is a fear not only of causing corneal perforation when such steroid drugs are applied to patients suffered from corneal herpes, corneal ulcer or the like, but also of induction of corneal herpes, keratomycosis, Pseudomonas infections and the like by the topical application of steroid drugs. As there has been known such-effects as above, steroid anti-inflammatory agents shall be applied with particular care. In spite of such a situation, it has not been known any non-steroid anti-inflammatory agent compatible with steroid anti-inflammatory drugs in effectiveness for the treatment of inflammatory ophthalmopathy such as uveitis. Thus, in the present stage in this technical field, for the treatment of inflammatory ophthalmopathy, it is hardly possible not to use steroid anti-inflammatory agents with particular care to avoid the side effects as above-mentioned. Under such circumstances, it is natural that ophthalmological experts are awaiting the appearance of non-steroid drugs which is effectively usable against uveitis or the like.

The present inventors investigated to find out topically applicable drugs with lesser side-effects and with superior effectiveness by which topically applicable drugs having been employed in the treatment of inflammatory ophthalmopathy, i.e. steroid anti-inflammatory agent, can be replaced. As the results, the present inventors unexpectedly found that certain derivatives of benzoylphenylacetic acid are very effective in the treatment of inflammatory ophthalmopathy, especially of uveitis, by topical application, and that the effectiveness of such drugs is compatible with that of conventional steroid anti-inflammatory drugs.

Furthermore, since we obtained the founding that there are some problems that the above-mentioned benzoylphenylacetic acid derivatives are unstable in an aqueous solution with the optimal pH range for a locally administrable therapeutic composition, we extensively investigated in search of the preparing method of a stable aqueous solution. As a result, we have succeeded in preparing a stable aqueous composition. Thus, the stable aqueous composition according to the invention are achieved based on the above finding.

While a number of non-steroid compounds fall under the category of anti-inflammatory agents, all of them are not effective in treating inflammatory eye diseases when topically administered to the eye. This is because there are several problems lying before them. First, when topically administered to the eye, a medicinal agent has to pass through the cornea so that it can reach the site of inflammation. Even when it has succeeded in arriving at the site of inflammation, it must remain there in a necessary concentration for a necessary period of time. If it fails to meet these requirements, it will be unable to produce expected


therapeutic effects. Furthermore, in case it is irritative to the eye, it is rather possible that the topical administration of the medicinal agent to the eye would cause exacerbation of symptoms. Therefore, great caution and much care are necessary in selecting a medicinal agent for topical administration to the eye. Furthermore, in case of administration in the form of eye drop, it goes without saying that it is desirable that the eye drop is stable for a long period of time in an aqueous solution without decomposition or forming insoluble matters.

Accordingly, it is an object of the invention to solve the above problems and provide a novel and useful agent for ophthalmic use.

Moreover, the other object of the invention is to provide a sufficiently stable aqueous solution such as eye drops, otic solution, nasal solution which contains the above compounds when stored for a long period of time.

SUMMARY OF THE INVENTION

The present invention, which has been completed on the above finding, provides a therapeutic administration to the eye for the treatment of inflammatory eye diseases which contains as active ingredient a benzoylphenylacetic acid of the formula



[wherein R is a hydrogen or halogen atom, or a salt thereof, or the hydrate of said acid or salt. In the formula, the halogen atom represented by R is, for example, fluorine, chlorine, bromine or iodine. The above compound to be used in accordance with the invention may be in a salt form. The salt includes alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, among others, and any salt may suitably be used provided that it can attain the object of the invention. The compounds defined above may be obtained in the form of a hydrate depending on the conditions of synthesis, recrystallization and so forth, and such form may be used in practicing the invention without any inconvenience or trouble.

Further, the above compounds may be unstable when stored in an aqueous solution for a long period of time, and there are some uneasinesses in the stability of an aqueous solution containing the compounds. Therefore we extensively investigated the stabilizing method in order to enhance the stability. As a result, unexpectedly, we have succeeded in stabilizing the solution by comprising incorporating a water-soluble polymer and sulfite and adjusting the pH to about 6-9.

DETAILED DESCRIPTION OF THE INVENTION

The compounds to be used as active ingredients in the topically administrable therapeutic compositions for inflammatory eye disease as well as nasal or otic disease in accordance with the invention (although such compositions are occasionally hereinafter referred to as "ophthalmic composition according to the present invention", use of an abbreviation does not exclude the application of the composition in nasal or otic field) can be produced as described in the above-cited report in Journal of Medicinal Chemistry, Volume 27, pages 1370-1388 (1984) or United States Patent No. 1,136, 375, for instance, or by a modification of the method described therein. The ophthalmic compositions according to the invention can be prepared in the form of eye-drop, eye ointments and so on in the same manner as various known compositions for topical administration to the eye. Thus, a compound of the above formula or a mixture of two or more compounds of the above formula is preferably made up into an aqueous or nonaqueous solution or mixed with an ointment base suited for ophthalmic use. On that occasion, an aqueous base generally used in the production of ophthalmic preparations, for example sterile distilled water, is suitably

used as the aqueous base and the pH thereof is adjusted to a level suited for topical administration to the eye. It is desirable that an appropriate buffer should be added in adjusting the pH. The pH of the ophthalmic compositions according to the invention is selected with due consideration paid to the stability and topical eye irritativity of the active ingredient, among others. According to the present invention, the stability of an aqueous composition containing the above compounds is remarkably enhanced by incorporating a water-soluble polymer and sulfite, and adjusting the pH to 6.0-9.0, preferably about 7.5-8.5. The eye irritation of the solution is not observed. A water-soluble polymer includes polyvinyl pyrrolidone, carboxypropylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, sodium salt of polyacrylic acid and so on, polyvinyl pyrrolidone is preferred of them. The concentration of a water-soluble polymer is in the range of about 0.1 to 10 w/w%. Sulfite includes sodium, potassium, magnesium, calcium salt and so on. The concentration of sulfite is in the range of about 0.1 to 1.0 w/w%. The pH adjustment is generally conducted with sodium hydroxide or hydrochloric acid, for instance, and it is advisable to form a buffer solution by combined use of, for example, sodium acetate, sodium borate or sodium phosphate and acetic acid, boric acid or phosphoric acid, respectively. The ophthalmic compositions according to the invention may further contain pharmaceutically active ingredients, such as an anti-inflammatory agent of another kind, an analgesic and an antimicrobial, unless they are unfit for the purpose of attaining the object of the invention. Examples of such antiinflammatory agent are indomethacin and pranoprofen. Usable examples of the antimicrobial agents are penicillins, cephalosporins, and synthetic antimicrobial agents of the quinolonecarboxylic acid series. Among these active ingredients for combined use with the active ingredient according to the invention, the anti-inflammatory agent is expected to be synergistic with said active ingredient in the ophthalmic compositions according to the invention, the analgesic is suited for the purpose of alleviating inflammation-associated pain, and the antimicrobial agent is suited for the purpose of preventing secondary infection. It is of course possible to incorporate other active agents than those mentioned above in the ophthalmic compositions according to the invention unless the object of the invention cannot be attained due to the presence thereof.

In preparing the ophthalmic compositions according to the invention as mentioned above, an isotonicizing agent, a microbicidal agent or preservative, a chelating agent, a thickening agent and so forth may be added to the compositions in accordance with the general practice of ophthalmic preparation manufacture. The isotonicizing agent includes, among others, sorbitol, glycerine, polyethylene glycol, propylene glycol, glucose and sodium chloride. The preservative includes para-oxybenzoic acid esters, benzyl alcohol, parachloro-meta-xyleneol, chlorocresol, phenetyl alcohol, sorbic acid and salts thereof, thimerosal, chlorobutanol, and the like. The chelating agent is, for example, sodium edetate, sodium citrate or sodium salt of condensed phosphoric acid. In preparing the ophthalmic compositions according to the invention in the form of eye ointments, the ointment base can be selected from among petrolatum, Macrogol, carboxymethylcellulose sodium, etc.

The ophthalmic composition according to this invention is prepared by incorporating the active compound in a base or vehicle for topical application to the eye. To prepare a liquid preparation, the concentration of the active ingredient may range from about 0.001 % to about 10 % and is preferably in the range of about 0.01 % to about 5 %. An ointment may be prepared by using the active compound in a concentration from about 0.001 % to about 10 %, preferably about 0.01 % to about 5 %. The ophthalmic composition of this invention may be administered in accordance with the following schedules. In the form of eye-drops, one to several drops per dose are instilled with a frequency of once to 4 times a day according to the clinical condition. Of course, the dosage may be adjusted according to symptoms. The ophthalmic composition according to this invention can be used topically for the treatment of inflammatory diseases of the eye without causing local irritant effects and produces beneficial effects surpassing those obtainable with the conventional drugs of the same type.

According to this invention, there can be obtained a stable aqueous composition such as otic composition or nasal composition. Other conventional methods can be used unless unsuitable for the object of this invention. Among others, an isotonicizing agent, buffer solution and preservatives can be used. The concentrations of the compounds of the invention varies depending on symptoms and so on, and usually may be in the range of about 0.001 to about 10 %, preferably about 0.01 to about 5 %.

The following experimental examples are given to delineate the efficacy profile of the ophthalmic composition of this invention and the stability of the aqueous compositions of the invention.

Anti-inflammatory effect of the ophthalmic agent according to this invention in experimental ophthalmitis induced by bovine serum albumin in white rabbits.

5 [Animals]

Seventeen male white rabbits weighing about 2 kg were used. They were fed with 80 g of Labo RG-RO (Nippon Agricultural Co., Ltd.) daily and had free access to tap water.

10

[Test drug]

Sodium 3-(4-bromobenzoyl)-2-aminophenylacetate monohydrate (hereafter referred to as Compound [I]) was used as 0.5 % and 0.1 % ophthalmic solutions. These ophthalmic solutions had a pH value of 8.11 and osmolarities of 310 mOsm/kg H₂O and 325 mOsm/kg H₂O, respectively. Bovine serum albumin (hereafter referred to as "BSA") was dissolved in physiological saline to a concentration of 5 % and sterilized by filtration. A 0.1 ml portion of the solution was injected into the central part of the vitreous of both eyes using a 27G needle under anesthesia with 0.4 % oxybuprocaine hydrochloride to induce ophthalmitis (ophthalmitis I). After 28 days when ophthalmitis I had nearly recovered, 2.5 % BSA solution was administered in a dose of 25 mg/ml/kg into the auricular vein to cause ophthalmitis (ophthalmitis II). The severity of ophthalmitis was rated according to the rating scale 1) of Yamauchi et al., based on the Draize method in which an increased weight given to the internal segment of the eye. Observation was made with a frequency of once in one or two days during the peak period of inflammation and once in three or four days before and after the peak period for ophthalmitis I and 3, 6, 12 and 24 hours after intravenous injection of BSA for ophthalmitis II.

[Results]

30

Anti-inflammatory effect in ophthalmitis I

Table 1 shows the sum of scores for respective parameters during a peak inflammatory period of 3 days after aseptic injection of 5 % BSA into the central part of the vitreous.

35

Table 2 shows the amount of protein, white blood cell count and the concentration of prostaglandins in the anterior chamber aqueous humor.

Anti-inflammatory effect in ophthalmitis II

40

The administration of 2.5 ml/kg of 2.5 % BSA solution into the auricular vein after 29 days when the inflammatory symptoms of ophthalmitis I had substantially subsided resulted in a relapse of inflammation after 3 hours in the physiological saline group, where both the external and internal segment of the eye after 12 hours showed inflammatory pictures similar to those observed at the peak of ophthalmitis I. These symptoms were still observed even after 24 hours. Table 3 shows the scores for respective parameters at 3, 6, 12 and 24 hours after the intravenous injection of BSA. Table 4 shows the amount of protein, white blood cell count and the concentration of prostaglandins in the anterior chamber aqueous humor.

50 Administration of the test drug

Gross observation was made on the day after injection of BSA into the vitreous body and with the animals arranged in the decreasing order of severity of ocular inflammation, grouping was carried out in such a manner that the intensity distribution would be uniform over the groups. Thus, a physiological saline

55

1) Hideyasu Yamauchi, Makoto Ingu, Tadashi Iso and Kozo Uda: Antiinflammatory effect of fluorometholone ophthalmic solution in experimental uvitis in rabbits. Folia Ophthalmologica Japonica, 24: 969-79 (1973)

group of 7 animals, a 0.1 % Compound [I] instillation group of 4 animals, a 0.5 % Compound [I] instillation group of 5 animals were provided. After this grouping procedure, the test drugs and saline were respectively instilled into both eyes of the rabbits, 50 μ l per dose, 4 times a day. For induction of ophthalmitis II, each drug was instilled into both eyes, 50 μ l per dose, immediately after injection of BSA into the auricular vein and at 1-hour intervals thereafter, for a total of 14 times.

Evaluation of results

In ophthalmitis I, Compound [I] at concentrations of 0.1 % and 0.5 % caused a potent and dose-dependent inhibition for both the external and the internal segment of the eye. Furthermore, at both concentration levels, Compound [I] produced a substantially complete inhibition of prostaglandins in the aqueous humor in ophthalmitis I.

In regard to the inhibitory effect on inflammatory symptoms, as evaluated by gross observation, which are induced by the intravenous injection of antigen, the Compound [I] according to this invention produced a substantially complete inhibition at both concentrations. As to white blood cell count, all drugs produced nearly the same degree of inhibition in both the internal and the external segments of the eye.

For any of the drugs, no body weight suppression was observed even after 28 consecutive days of treatment. In the organs including the thymus, spleen, adrenal and so on, anatomically no abnormality was found.

Experimental Example 2

The effect of the compounds according to this invention on carrageenin edema in rats

Test drugs

1. Sodium 3-(4-bromobenzoyl)-2-aminophenyl-acetate (hereinafter referred to as Compound [I])
2. Sodium 3-(4-chlorobenzoyl)-2-aminophenyl-acetate (hereinafter referred to as Compound [II])
3. Sodium 3-benzoyl-2-aminophenylacetate (hereinafter referred to as Compound [III])

Method

Using female Wister rats weighing 100 g in groups of 5 animals or 10 eyes, 0.05 ml of 1 % carrageenin (dissolved in physiological saline at 50 °C) as a phlogogen was injected beneath the conjunctiva of both eyes to induce edema. Physiological saline, as a control, and test drugs were respectively instilled into both eyes 40 and 20 minutes before and immediately after the injection of carrageenin, in the amount of 2.5 μ l per dose. Four hours after the phlogogen treatment, each animal was sacrificed by cervical dislocation and in accordance with the method of Maistrello et al. 2), the scalp was peeled off toward the eyelid and the edematous portion together with the skin was removed along the lid margin and weighed. The degrees of inhibition of carrageenin edema in the control group and drug treatment group are shown in Table 5. Each drug group showed a significant difference from the control group, indicating the effectiveness of the three compounds against acute ocular inflammation.

Experimental Example 3

2) Maistrello et al.: Quantitative Effect of Topically Applied Anti-inflammatory Agents on External Ocular Inflammation in Rats: Journal of Pharmaceutical Science, volume 62, pp. 1455-60(1973)

Effects on atropine-resistant miosis and on protein increase after paracentesis

The experiment was divided into two parts, i.e. Experiment 3.a, in which the effect of Compound [I] was evaluated, and Experiment 3.b, in which indomethacin, the most known anti-inflammatory drug with strong cyclooxygenase inhibitory activity, was evaluated.

[Test drugs]

The solutions of the following formulas were used.

a. Compound [I]				
Compound [I]	0.1	0.01	0.001	0.0001%
Boric acid	1.0	1.0	1.0	1.0 %
Borax	q.s.	q.s.	q.s.	q.s.
Sodium chloride	0.25	0.25	0.25	0.25 %
Sodium edetate	0.02	0.02	0.02	0.02 %
Benzalkonium chloride	0.005	0.005	0.005	0.005 %
Tween 80	0.3	0.3	0.3	0.3 %
(pH 8.0, Osmotic pressure 310 mOsm/Kg * H ₂ O)				
b. Indomethacin				
Indomethacin	0.5%			
Castor oil	q.s.			

[Animals]

Totally 28 male albino rabbits (4 rabbits X 7 groups) with the body weight of about 2kg were used. They had been confirmed, before the experiment, to have mydriatic response to 1 % atropine for at least 4 hours.

[Test procedure]

50 μ l each of 1% atropine solution was instilled into both eyes of the animals one hour before the 1st paracentesis, in which approx. 0.2 ml/eye of aqueous humor (primary aqueous humor) was collected. Topical application of 50 μ l each of the test drug solutions was conducted 30 min before the paracentesis. Pupil diameter of each eye was measured with a slide caliper immediately before and 10 min after the paracentesis. The 2nd paracentesis was conducted 90 min after the 1st one, in which approx. 0.2 ml/eye of aqueous humor (secondary aqueous humor) was collected.

[Results]

As shown in Table 6, Compound [I] exhibited a dose-related inhibitory activity on miosis after paracentesis at the concentrations of 0.0001-0.1%, whereas little effect was observed with indomethacin at the concentrations as high as 0.5%. As shown in Table 7, Compound [I] exhibited a strong and dose-related inhibitory activity on protein increase after paracentesis, in which the effect of 0.01% of Compound [I] was equivalent to that of 0.5% indomethacin. It is well known that atropine-resistant miosis and protein increase in aqueous humor after paracentesis are caused by prostaglandin E₂, which is one of the most important chemical mediators of inflammation and is synthesized immediately after mechanical injury. The results,

therefore, indicate that Compound [I] has stronger anti-inflammatory effect than indomethacin.

Experimental Example 4

The effects of pH changes on the compound [I]

Formula	
Compound [I]	0.1 g
Borax	1.0 g
Sodium borate	Sufficient quantity
Sodium chloride	0.25 g
Disodium edetate	0.02 g
Benzalkonium chloride	0.005 g
Polysorbate 80	0.3 g
Sterile purified water	To make 100 ml

We observed the stability at 60 °C of the compound by changing pH (6.0, 7.0, 8.0 and 9.0) of the above formula. The results are shown in Table 8.

Of the above four, the formula at the pH of 8 is most stable. In the formula, the change in residue rate were not almost observed but in three weeks red insoluble matters were observed.

Experimental example 5

As a result of extensive examination on preventing the red insoluble matters, we observed the stability by incorporating polyvinyl pyrrolidone.

Formulas	B-1	B-2
Compound [I]	0.1 g	0.1 g
Boric acid	1.5 g	1.5 g
Borax	Sufficient quantity	
Disodium edetate	0.02 g	0.02 g
Benzalkonium chloride	0.007 g	0.007 g
Polysorbate 80	0.15 g	0.15 g
Polyvinyl pyrrolidone	2.0 g	—
Sterile purified water	To make 100 ml	
	pH 8	pH 8

In the above formulas, the results of the stability at 60 °C are as follows (Tables 9):

It was found that by incorporating polyvinyl pyrrolidone, the appearance of red insoluble matters was considerably prevented. In four weeks, however, some insoluble matters were observed.

Experimental example 6

Moreover, as a result of searching for more stable solutions, we obtained the finding that by further incorporating sodium sulfite other than polyvinyl pyrrolidone, the stability was remarkably increased.

Formulas	B	B-3
Compound [I]	0.1 g	0.1 g
Boric acid	1.5 g	1.5 g
Borax	Sufficient quantity	
Disodium edetate	0.02 g	0.02 g
Benzalkonium chloride	0.007 g	0.007 g
Polyvinyl pyrrolidone	0.15 g	0.15 g
Sodium sulfite	—	0.2 g
Sterile purified water	To make 100 ml	
	pH 8	pH 8

As shown in Table 10, the change of appearance was observed in the formula in which sodium sulfite was not incorporated, and the residue increased by about 7 %. By contrast, in the solution containing Compound [I] in which polyvinyl pyrrolidone and sodium sulfite coexist, the change of appearance was not observed at all and the decomposition of Compound [I] was not observed either. It was found that the stability was remarkably enhanced. Thus, there can be successfully obtained a stable aqueous composition containing the compounds.

The following are explanatory examples of the ophthalmic composition and other stable aqueous compositions according to the invention.

Example 1

3-(4-Bromobenzoyl)-2-aminophenylacetate monohydrate	0.1 %
Boric acid	1.0 %
Borax	Sufficient quantity
Sodium chloride	0.25 %
Sodium edetate	0.02 %
Benzalkonium chloride	0.005 %
Polysorbate 80	0.3 %
Purified water	Sufficient quantity

The above ingredients are made up into an ophthalmic solution (the total volume being 100 ml) and pH is adjusted to 8.0.

Example 2

Sodium 3-benzoyl-2-amino-phenylacetate	0.1 %
Boric acid	1.0 %
Borax	0.02 %
Sodium chloride	0.25 %
Sodium edetate	Sufficient quantity
Benzalkonium chloride	0.005 %
Polysorbate 80	0.3 %
Purified water	Sufficient quantity

The above ingredients are made up into an ophthalmic solution (the total volume being 100 ml) and pH is adjusted to 8.0.

Example 3

5	Sodium 3-(4-chlorobenzoyl)-2-aminophenylacetate	1.0 %
	White petrolatum	Sufficient quantity

The above ingredients are mixed up into an eye ointment (100 g) in the conventional manner.

10

Example 4

15	Sodium 3-(4-chlorobenzoyl)-2-aminophenylacetate monohydrate	0.01 g
	Carboxymethylcellulose	Sufficient quantity

conventional manner to give 100 g of an eye ointment.

20

Example 5

25	Sodium 3-(4-chlorobenzoyl)-2-aminophenylacetate monohydrate	1.0 g
	Sodium chloride	0.8 g
	Tween 80	0.2 g
	Purified water	Sufficient quantity

30 The above ingredients are made up into an ophthalmic solution (the total volume being 100 ml) and the pH is adjusted to 7.5 with hydrochloric acid.

Example 6 Ophthalmic Solution

35

40	3-(4-bromobenzoyl)-2-aminophenylacetate monohydrate	0.1 g
	Boric acid	1.25 g
	Borax	1.0 g
	Disodium edetate	0.02 g
	Benzalkonium chloride	0.005 g
	Polysorbate 80	0.15 g
	Polyvinyl pyrrolidone	2.0 g
45	Sodium sulfite	0.2 g
	Sterile purified water	To make 100 ml
	pH 8	

50 Example 7 Ophthalmic Solution

55

	3-(4-bromobenzoyl)-2-aminophenylacetate monohydrate	0.1 g
	Boric acid	0.7 g
	Borax	Sufficient quantity
5	Sodium chloride	0.5 g
	Polysorbate 80	0.15 g
	Methylparaben	0.013 g
	Ethylparaben	0.007 g
	Polyvinyl pyrrolidone	2.0 g
	Sodium sulfite	0.2 g
10	Sodium edetate	0.02 g
	Sterile purified water	To make 100 ml

15 Example 8 Ophthalmic Solution

	3-(4-bromobenzoyl)-2-aminophenylacetate monohydrate	0.1 g
	Boric acid	1.5 g
20	Borax	Sufficient quantity
	Benzalkonium chloride	0.005 g
	Polysorbate 80	0.15 g
	Polyvinyl pyrrolidone	2.0 g
25	Sodium sulfite	0.1 g
	Sterile purified water	To make 100 ml
	pH 8	

30 The following (Table 11) are the residue and appearance of the compositions in Examples 6-8 after 4 weeks at 60° C.

As shown in Table 11, it was found that changes in appearances of the compositions were not observed at all, and the decomposition of the compound was not almost observed, the aqueous compositions being stable, excellent for a long period of time.

35

Example 9 Ophthalmic Solution

40	3-(4-bromobenzoyl)-2-aminophenylacetate monohydrate	0.1 g
	Sodium monohydrogen phosphate	0.2 g
	Sodium dihydrogen phosphate	Sufficient quantity
	Sodium chloride	0.8 g
	Benzalkonium chloride	0.007 g
45	Polysorbate 80	0.15 g
	Polyvinyl alcohol	1.0 g
	Potassium sulfite	0.2 g
	Sterile purified water	To make 100 ml
50	pH 8	

Example 10 Nasal and Otic Solution

55

3-(4-bromobenzoyl)-2-aminophenylacetate monohydrate	0.1 g
Boric acid	0.1 g
Borax	Sufficient quantity
Sodium chloride	0.8 g
Methylparaben	0.3 g
Ethylparaben	0.1 g
Polyvinyl pyrrolidone	2.0 g
Sodium sulfite	0.1 g
Sterile purified water	To make 100 ml
pH 7.5	

Table 1

Parameter		Test Drug	Physiological saline (14) ^{a)}	Compound (I) 0.1% (8) ^{a)}	Compound (I) 0.5% (10) ^{a)}
External Segment	Corneal opacity		2.5±0.5	1.0±0.4 (60.0) ^{b)}	0.4±0.2 ^{**} (48.0) ^{b)}
	Palpebral conjunctival injection		3.8±0.5	1.3±0.2 ^{**} (65.8) ^{b)}	1.5±0.3 ^{**} (36.8) ^{b)}
	Palpebral conjunctival edema		0.7±0.3	0.1±0.1 (85.7) ^{b)}	0 ^{**} (100) ^{b)}
	Bulbar conjunctival injection		6.5±0.7	4.5±0.6 (30.8) ^{b)}	1.6±0.2 ^{**} (74.5) ^{b)}
	Discharge		0.3±0.1	0 ^{**} (100) ^{b)}	0 ^{**} (100) ^{b)}
	Total Score		13.7±1.9	6.8±1.0 ^{**} (50.4) ^{b)}	3.5±0.4 ^{**} (74.5) ^{b)}
Internal Segment	Anterior chamber opacity		3.0±0.3	3.6±0.8 (-20.0) ^{b)}	2.0±0.4 (33.3) ^{b)}
	Iridic injection		6.1±0.6	2.6±0.2 ^{**} (57.4) ^{b)}	1.8±0.2 ^{**} (70.5) ^{b)}
	Morphological change of iris		4.4±0.2	2.9±0.4 ^{**} (34.1) ^{b)}	2.9±0.4 ^{**} (34.1) ^{b)}
	Total Score		13.5±0.8	9.1±1.0 ^{**} (32.6) ^{b)}	6.6±0.8 ^{**} (51.1) ^{b)}
External + Internal	Grand Total Score		27.3±2.5	15.9±1.8 ^{**} (41.8) ^{b)}	10.1±1.0 ^{**} (63.0) ^{b)}

55 [Notes to Table 1]

Each value represents the mean ± standard error. The figure in parentheses ^{a)} represents the number of cases, and the figure in parentheses ^{b)} represents the degree (%) of inhibition relative to the physiological

saline group. Significant differences from the physiological saline group at the levels of $^1p < 0.05$, $^2p < 0.01$ and $^3p < 0.001$.

Table 2

Drug	Concentration %	Number of Cases	Protein ng/ml	White Blood Cell Cells/mm ³	Prostaglandin ng/ml
Physiological saline	—	7	50.3±7.3	5869±2194	1.89 ±0.75
Compound (I)	0.1	4	48.7±3.8	5593±3436	<0.4 ^{a)}
	0.5	5	28.4±1.6 ^{a)}	1980± 654	<0.4 ^{a)}

(Notes to Table 2)

Each value represents the mean \pm standard error; * means that the concentration is less than the assay limit (0.4 ng/ml); * means a significant difference from the physiological saline group at $p < 0.05$.

Table 3

Parameter		Test Drug	Physiological saline (14) ^{a)}	Compound (I) 0.1% (8) ^{a)}	Compound (I) 0.5% (10) ^{a)}
External Segment	Corneal opacity		1.4±0.3	0.6±0.2 (57.1) ^{b)}	0.6±0.2 (57.1) ^{b)}
	Palpebral conjunctival injection		5.7±0.7	4.0±0.3 (29.8) ^{b)}	3.7 ±0.1 ^{a)} (60.5) ^{b)}
	Palpebral conjunctival edema		2.0±0.8	1.1±0.4 (45.0) ^{b)}	0.9±0.2 (55.0) ^{b)}
	Balbar conjunctival injection		11.1±0.6	8.1±0.4 (27.0) ^{b)}	8.1±0.3 ^{a)} (27.0) ^{b)}
	Discharge		0.3±0.1	0 (100) ^{b)}	0 (100) ^{b)}
	Total Score		20.5±2.5	13.1±1.1 ^{a)} (32.7) ^{b)}	13.3±0.6 ^{a)} (31.4) ^{b)}
Internal Segment	Anterior chamber opacity		1.9±0.3	2.8±0.8 (-47.4) ^{b)}	2.8±0.5 (-47.4) ^{b)}
	Iridic injection		7.3±0.8	2.8±0.1 ^{a)} (61.6) ^{b)}	3.3±0.3 ^{a)} (54.8) ^{b)}
	Morphological change of iris		4.3±0.5	2.4±0.4 ^{a)} (44.2) ^{b)}	2.9±0.3 ^{a)} (32.6) ^{b)}
	Total Score		13.5±1.1	8.0±1.2 ^{a)} (40.7) ^{b)}	9.0±0.7 ^{a)} (33.3) ^{b)}
External + Internal	Grand Total Score		33.9±3.5	21.8±2.1 ^{a)} (35.7) ^{b)}	22.3±1.1 ^{a)} (34.2) ^{b)}

[Notes to Table 3]

Each value represents the mean \pm standard error. The figure in parentheses ^{a)} represents the number of cases, and the figure in parentheses ^{b)} represents the degree (%) of inhibition relative to the physiological saline group. Significant differences from the physiological saline group at the levels of ^{*} = $p < 0.05$, and ^{**} = $p < 0.01$.

Table 4

Drug	Concentration %	Number of Cases	Protein mg/ml	White Blood Cell Cells/mm ³	Prostaglandin ng/ml
Physiological saline	—	10	39.5 \pm 2.20	2416 \pm 478	15.79 \pm 4.86
Compound [I]	0.1	8	48.7 \pm 3.8	1489 \pm 499	<0.4 ^{a) *}
	0.5	10	28.4 \pm 1.6 ^{**}	1673 \pm 277	<0.4 ^{a) **}

[Notes to Table 4]

Each value represents the mean \pm standard error; ^{a)} means that the concentration is less than the assay limit (0.4 ng/ml); ^{*} means a significant difference from the physiological saline group at the level of ^{*} = $p < 0.05$, and ^{**} = $p < 0.01$.

Table 5

Compound	Concentration (%)	Weight of Edema* (mg)	Degree of inhibition (%)
Compound [I]	1.0	43.93 \pm 4.138	16.9 ^{**}
	2.5	36.323 \pm 3.308	31.3 ^{**}
Compound [III]	1.0	30.98 \pm 3.194	41.4 ^{**}
	5.0	32.80 \pm 2.409	37.9 ^{**}
Control	-	52.17 \pm 2.401	-
Compound [II]	0.5	37.52 \pm 2.423	36.9 ^{**}
	1.0	39.02 \pm 3.057	34.4 ^{**}
Control	-	59.47 \pm 3.057	-

[Notes to Table 5]

* Each value represents the mean \pm standard error for 10 eyes.** Significant differences from the control group at $p < 0.001$.

Table 6

Test drug	Content(%)	Miosis(%)	Inhibition(%)
Physiological salin	-	23.7 ±1.94	-
Exp.3,a	0.1	17.4 ±3.80	24.9±16.4
	0.01	15.4 ±1.60 *2	35.2±6.75
	0.001	19.0 ±1.44	19.7±6.08
	0.0001	21.5 ±1.97	9.2±8.33
Physiological saline	-	17.6 ±1.88	-
Indomethacin	0.5	16.4 ±3.86	6.0±21.4
t-test			

*2 : P<0.01

Table 7

Test drug	Content(%)	Primary aqueous humor	Secondary aqueous humor	Inhibition(%)
		Protein(μg/ml)	Protein(μg/ml)	
Physiological saline	-	0.89±0.20	25.04±4.12	-
Exp.3,b	0.1	0.76±0.20	3.06±0.46 *2	87.8
	0.01	0.39±0.04 *1	9.29±7.30 *2	62.9
	0.001	0.38±0.02 *1	18.45±3.53	26.3
	0.0001	0.44±0.06	23.45±1.67	6.3
Physiological saline	-	0.84±0.11	20.21±1.79	-
Indomethacin	0.5	0.77±0.10	6.13±1.64 *3	69.7
t-test				

*1 : P<0.05

*2 : P<0.01

*3 : P<0.001

Table 8

	Formula	pH	Appearance	Residue (%)
1 Week	A-1	pH 6.0	+	38.6
	-2	pH 7.0	+	79.3
	-3	pH 8.0	-	100.5
	-4	pH 9.0	-	101.1
2 Weeks	A-1	pH 6.0	+	23.9
	-2	pH 7.0	+	63.7
	-3	pH 8.0	-	98.6
	-4	pH 9.0	-	99.4
3 Weeks	A-1	pH 6.0	+	19.3
	-2	pH 7.0	+	54.2
	-3	pH 8.0	-	98.0
	-4	pH 9.0	-	99.0
Note:				
The symbol "-" denotes that change in appearance was not observed.				
The symbol "+" denotes that change in appearance was observed.				
(hereinafter, the same as above)				

Table 9

Formula	1 Week	2 Weeks	3 Weeks
B-1	-	-	-
B-2	-	-	+

Table 10


Formula	Residue (%)	Appearance
B-1	93.4	+
B-3	100.9	-

Table 11

	Appearance	Residue (%)
Example 6	-	100.9
Example 7	-	99.2
Example 8	-	98.9


Claims

1. A locally administrable therapeutic composition for inflammatory disease which is characterized by comprising benzoylphenylacetic acid of the formula



[wherein R is a hydrogen or halogen atom, or a salt thereof, or the hydrate of said acid or salt, as active ingredient.

2. A locally administrable stable therapeutic composition for inflammatory disease, which comprises benzoylphenylacetic acid of the formula



(wherein R is a hydrogen or halogen atom), or a salt thereof, or the hydrate of said acid or salt, as active ingredient; a water-soluble polymer and sulfite; and the pH of which is in the range of about 6-9.

3. The locally administrable therapeutic composition for inflammatory disease according to claim 2, wherein the water-soluble polymer is polyvinyl pyrrolidone, polyvinyl alcohol, carboxypropylcellulose, hydroxyethylcellulose, hydroxypropylcellulose or sodium salt of polyacrylic acid.

4. The locally administrable therapeutic composition for inflammatory disease according to claim 2, wherein the concentration of the water-soluble polymer is in the range of about 0.1-10 W/W%.

5. The locally administrable therapeutic composition for inflammatory disease according to claim 2, wherein the sulfite is in the form of sodium, potassium, calcium or magnesium salt.

6. The locally administrable therapeutic composition for inflammatory disease according to claim 2, wherein the concentration of the sulfite is in the range of about 0.1-1 W/W%.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 89 10 1237

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	PATENT ABSTRACTS OF JAPAN, vol. 8, no. 41 (C-211)[1478], 22nd February 1984; & JP-A-58 201 710 (MEIJI SEIKA K.K.) 24-11-1983 * Abstract *	1,3	A 61 K 47/00 A 61 K 31/195
D,X	EP-A-0 221 753 (ROBINS) * Claims; page 4, lines 11-14; page 30, lines 32-34 *	1,3	
D,A	* Page 29, lines 35-37 * -----	2	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 22-05-1989	Examiner SCARPONI U.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			